$6.70
3.32% yesterday
Nasdaq, Jul 01, 10:00 pm CET
ISIN
US6024961012
Symbol
MDXG
Sector
Industry

MiMedx Group, Inc. Target price 2024 - Analyst rating & recommendation

MiMedx Group, Inc. Classifications & Recommendation:

Buy
100%

MiMedx Group, Inc. Target price

Target price $12.67
Course $6.70
Price potential
Number of estimates 6
6 Analysts have issued a price target MiMedx Group, Inc. 2025 . The average MiMedx Group, Inc. target price is $12.67. This is higher than the current share price. The highest price target is , the lowest is .
A rating was issued by 5 analysts: 5 Analysts recommend MiMedx Group, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst estimates: Analysts believe that the MiMedx Group, Inc. share has an average upside potential 2025 of . Most analysts recommend the MiMedx Group, Inc. share at Purchase.

Sales and margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Forecast
Turnover Million $ 321.48 359.88
20.03% 11.94%
EBITDA margin 12.61% 22.13%
271.71% 75.49%
Net margin 14.69% 12.57%
180.79% 14.40%

6 Analysts have issued a sales forecast MiMedx Group, Inc. 2024 . The average MiMedx Group, Inc. sales estimate is

$360m
unlock
. This is
7.58% higher
unlock
than the turnover of the last 12 months(TTM). The highest sales forecast is
$365m 9.20%
unlock
, the lowest is
$350m 4.66%
unlock
.

This results in the following potential growth figures:

Sales forecast

2023 $321m 20.03%
2024
$360m 11.94%
unlock
2025
$407m 12.98%
unlock
2026
$478m 17.55%
unlock
2027
$487m 1.90%
unlock
2028
$554m 13.73%
unlock

3 Analysts have issued an MiMedx Group, Inc. EBITDA forecast 2024. The average MiMedx Group, Inc. EBITDA estimate is

$79.6m
unlock
. This is
61.20% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$81.7m 65.38%
unlock
, the lowest is
$76.0m 53.85%
unlock
.

This results in the following potential growth figures and future EBITDA margins:

EBITDA forecast

2023 $40.5m 306.10%
2024
$79.6m 96.43%
unlock
2025
$89.8m 12.73%
unlock
2026
$108m 19.87%
unlock

EBITDA margin

2023 12.61% 271.71%
2024
22.13% 75.49%
unlock
2025
22.08% 0.23%
unlock
2026
22.51% 1.95%
unlock

6 MiMedx Group, Inc. Analysts have issued a net profit forecast 2024. The average MiMedx Group, Inc. net profit estimate is

$45.2m
unlock
. This is
33.34% lower
unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$54.6m 19.56%
unlock
, the lowest is
$36.9m 45.66%
unlock
.

This results in the following potential growth figures and future net margins:

Net profit forecast

2023 $47.2m 196.97%
2024
$45.2m 4.17%
unlock
2025
$61.2m 35.32%
unlock
2026
$98.9m 61.47%
unlock
2027
$97.4m 1.50%
unlock
2028
$133m 36.37%
unlock

Net margin

2023 14.69% 180.79%
2024
12.57% 14.40%
unlock
2025
15.06% 19.81%
unlock
2026
20.68% 37.32%
unlock
2027
19.99% 3.34%
unlock
2028
23.97% 19.91%
unlock

Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Forecast
Earnings per share $ 0.32 0.31
196.97% 3.13%
P/E ratio 21.85
EV/Sales 2.67

6 Analysts have issued a MiMedx Group, Inc. forecast for earnings per share. The average MiMedx Group, Inc. <a href=/blog/eps>EPS is

$0.31
unlock
. This is
32.61% lower
unlock
than earnings per share in the financial year 2023. The highest <a href=/blog/eps>EPS forecast is
$0.37 19.57%
unlock
, the lowest is
$0.25 45.65%
unlock
.

This results in the following potential growth figures and future valuations:

Earnings per share

2023 $0.32 196.97%
2024
$0.31 3.13%
unlock
2025
$0.42 35.48%
unlock
2026
$0.67 59.52%
unlock
2027
$0.66 1.49%
unlock
2028
$0.90 36.36%
unlock

P/E ratio

Current 14.43 150.07%
2024
21.85 51.42%
unlock
2025
16.14 26.13%
unlock
2026
10.00 38.04%
unlock
2027
10.15 1.50%
unlock
2028
7.44 26.70%
unlock

Based on analysts' sales estimates for 2024, the MiMedx Group, Inc. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of

and an <a href=/blog/kurs-umsatz-verhaeltnis-kuv-einfach-erklaert>P/S ratio of .

This results in the following potential growth figures and future valuations:

EV/Sales

Current 2.87 4.65%
2024
2.67 7.06%
unlock
2025
2.36 11.49%
unlock
2026
2.01 14.93%
unlock
2027
1.97 1.87%
unlock
2028
1.73 12.08%
unlock

P/S ratio

Current 2.96 8.57%
2024
2.75 7.05%
unlock
2025
2.43 11.49%
unlock
2026
2.07 14.92%
unlock
2027
2.03 1.87%
unlock
2028
1.79 12.07%
unlock

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now